PARIS, NEW YORK and SINGAPORE, Oct. 13, 2025 /PRNewswire/ — AMTD Group Inc. (“AMTD” or the “Group”), alongside The Generation Essentials Group (“TGE”, NYSE: TGE), a subsidiary of the Group under AMTD Digital (NYSE: HKD), jointly announce that AMTD’s blockbuster film “The Last Dance” has been selected by the Federation of Motion Film Producers of Hong Kong to represent the Hong Kong Special Administrative Region in the Best International Feature Film category at the 98th Oscar Academy Awards.

Beyond this honor, this AMTD film has also received five nominations at the 38th Golden Rooster Awards, including Best Feature Film, Best Director, Best Screenplay, Best Actress, and Best Editing. 

Since its release, “The Last Dance” has achieved critical acclaim and commercial success. It grossed over US$20 million in Hong Kong and Macau, becoming the highest-grossing Chinese-language film in Hong Kong history. Globally, total box office has exceeded US$50 million. This AMTD film has already achieved multiple awards at international film festivals. It was a major winner at the 43rd Hong Kong Film Awards, securing awards for Best Original Film Score, Best Screenplay, Best Original Song, Best Supporting Actor, and Best Actress.

AMTD is one of the production companies of this movie, with Dr. Calvin Choi, founder of AMTD IDEA Group and AMTD Digital serving as producer.

About AMTD Group

AMTD Group is a conglomerate with a core business portfolio spanning across media and entertainment, education and training, and premium assets and hospitality sectors.

About AMTD IDEA Group

AMTD IDEA Group (NYSE: AMTD; SGX: HKB) represents a diversified institution and digital solutions group connecting companies and investors with global markets. Its comprehensive one-stop business services plus digital solutions platform addresses different clients’ diverse and inter-connected business needs and digital requirements across all phases of their life cycles. AMTD IDEA Group is uniquely positioned as an active super connector between clients, business partners, investee companies, and investors, connecting the East and the West. For more information, please visit www.amtdinc.com or follow us on X (formerly known as “Twitter”) at @AMTDGroup.

About AMTD Digital Inc.

AMTD Digital Inc. (NYSE: HKD) is a comprehensive digital solutions platform headquartered in France. Its one-stop digital solutions platform operates key business lines including digital media, content and marketing services, investments as well as hospitality and VIP services. For AMTD Digital’s announcements, please visit https://ir.amtdigital.net/investor-news.

About The Generation Essentials Group

The Generation Essentials Group (NYSE: TGE), jointly established by AMTD Group, AMTD IDEA Group (NYSE: AMTD; SGX: HKB) and AMTD Digital Inc. (NYSE: HKD), is headquartered in France and focuses on global strategies and developments in multi-media, entertainment, and cultural affairs worldwide as well as hospitality and VIP services. TGE comprises L’Officiel, The Art Newspaper, movie and entertainment projects. Collectively, TGE is a diversified portfolio of media and entertainment businesses, and a global portfolio of premium properties.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about the beliefs, plans, and expectations of AMTD IDEA Group and/or AMTD Digital, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in the filings of AMTD IDEA Group, AMTD Digital and The Generation Essentials Group with the SEC. All information provided in this press release is as of the date of this press release, and none of AMTD IDEA Group, AMTD Digital and The Generation Essentials Group undertakes any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

For AMTD IDEA Group: 
IR Office
AMTD IDEA Group
EMAIL: ir@amtdinc.com 

For AMTD Digital Inc.: 
IR Office
AMTD Digital Inc.
EMAIL: ir@amtdigital.net 

 For The Generation Essentials Group:
IR Office
The Generation Essentials Group
EMAIL: tge@amtd.world

TORONTO, Oct. 13, 2025 /PRNewswire/ — Visionary Holdings Inc. (“GV” or the “Company”), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary, Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. (“Yike”). The agreement grants GV the worldwide rights to apply Yike’s breakthrough stem cell technology, which has demonstrated significant potential in advancing treatments for diabetes and with other regenerative medicine innovations.

Under the agreement, GV is authorized to utilize Yike’s proprietary regenerative medicine technology platform and jointly advance the commercialization and clinical application of related products. The collaboration will focus on key areas such as stem cell therapy, anti-aging biological repair, and cellular rejuvenation:

1. The core stem cell technology system targeting both Type 1 and Type 2 diabetes has conducted clinical trials and the results demonstrated the potential to achieve long-term remission and even complete cure, representing a significant global breakthrough in regenerative medicine and metabolic disease treatment;
2. Integrated stem cell-based therapeutic technologies targeting for immune diseases and metabolic disorders;
3. Technologies for cell preparation, storage, quality control, and clinical application of stem cells.

GV will leverage its international commercialization network, clinical collaboration channels, and operational expertise to introduce and expand the application of these technologies across global market.

Under the revenue-sharing arrangement, both parties will share returns based on actual product sales and technology commercialization achievements. Yike will primarily generate revenue from technology licensing and clinical R&D, while GV will benefit from market sales, brand operations, and global business development. Yike will continue to provide scientific leadership and technical support, ensuring the sustained competitiveness and continuous innovation of the joint technology platform.

Xiyong Hou, CEO of Visionary Holdings, commented:

“This global license for Yike’s stem cell technology marks a major milestone in GV’s global health strategy. Diabetes currently affects more than 540 million adults worldwide, with the global treatment market exceeding USD 150 billion in 2024 and continuing to grow steadily. Existing therapies primarily manage blood glucose and delay complications, but do not offer a definitive cure. Preclinical and clinical studies have shown positive results in restoring pancreatic islet function in patients with both Type 1 and Type 2 diabetes, demonstrating the potential to achieve long-term remission and even complete cure across a broad patient population. Yike’s stem cell therapy has demonstrated the potential to restore pancreatic islet function and achieve long-term diabetes remission, offering new hope to millions of patients worldwide.

By combining Yike’s cutting-edge regenerative science with GV’s global commercialization capabilities, we aim to deliver transformative medical solutions to patients worldwide. We are confident that this collaboration will not only generate meaningful health benefits but also contribute significantly to GV’s revenue growth in upcoming fiscal years.”

Looking ahead, GV and Yike plan to further deepen their cooperation in product R&D, clinical validation, and international market expansion, while jointly exploring global certification standards for regenerative medical products. This partnership lays a strong foundation for GV’s continued growth and leadership in the rapidly evolving global medical technology sector.

About Visionary Holdings Inc.
Visionary Holdings Inc. (Nasdaq: GV) is a technology-driven multinational enterprise focused on innovative education, AI applications, and high-tech healthcare solutions. Headquartered in Toronto, Canada, the Company operates through its subsidiaries across North America and Asia, driving technological advancement, cross-border innovation, and global health transformation.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook,” “objective” and similar terms. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond GV’s control, which may cause GV’s actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to GV as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in GV’s filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. GV does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts:

Visionary Holdings Inc.
Investor Relations
Email: IR@visionary.holdings

HANGZHOU, China, Oct. 13, 2025 /PRNewswire/ — Jiuzi Holdings, Inc. (NASDAQ: JZXN, hereinafter referred to as the “Company”) today elaborated on the progress of its cryptocurrency-denominated private placement transaction. The total consideration for this transaction was settled using 100 Bitcoin.

This capital operation pioneers a new paradigm combining traditional equity financing with digital assets, fully demonstrating market recognition of JZXN’s strategic layout in the cryptocurrency sector. The raised funds will be exclusively allocated to two strategic directions: constructing an intelligent digital asset custody platform, and developing cutting-edge technology-based encrypted storage systems. These initiatives aim to strengthen the Company’s infrastructure service capabilities in the digital economy era.

Since the disclosure of the transaction framework, market response has been positive, with the Company’s stock price showing a steady upward trend and maintaining a sustained premium over its closing price prior to the announcement. This trend not only reflects investor endorsement of the innovative transaction structure but also highlights strong interest from capital markets in emerging digital financial instruments.

“From signing the agreement on October 7th to its current implementation phase, we have consistently prioritized balancing compliance and innovation,” stated Tao Li, CEO of JZXN. “These Bitcoin-denominated funds will be primarily invested in R&D for underlying blockchain technologies, particularly in key areas like secure multiparty computation and zero-knowledge proofs, laying the foundation for building next-generation digital financial service platforms.”

About JZXN

As a leading domestic provider of new energy infrastructure services, Jiuzi Holdings specializes in developing charging networks across third- and fourth-tier cities. Its high-power DC fast charging stations, integrated with energy storage systems, have achieved significant scaled operational advantages. Concurrently, the Company is advancing its “Smart Energy Cloud Platform” project, planning to enable intelligent interaction between charging facilities and power grid systems via Internet of Things (IoT) technology. Leveraging proceeds from this private placement, it will also initiate R&D testing for cross-border digital payment solutions, further expanding its business horizons. For more information, please visit jzxn.com.

HONG KONG, Oct. 13, 2025 /PRNewswire/ — In a major development for China’s cosmetic industry, CHANDO Group, a leading homegrown cosmetics brand, has completed a new round of financing. Harvest Capital has invested ¥300 million (over US$40 million) in this round, with global beauty giant L’Oréal also participating as an industrial partner. This historic collaboration signals the beginning of a new chapter for CHANDO Group, as it joins forces with well-known consumer funds and international industry leaders to propel the company toward high-quality, sustainable growth.

Two Decades of Beauty Leadership: Building a Multi-Brand, Full Supply Chain, and Digitally-Driven Enterprise

Founded in 2001, CHANDO Group has consistently adhered to its brand philosophy, “Beautiful, as you are.” dedicating itself to providing consumers worldwide with affordable, high-quality products for beauty and healthy living. According to data from Frost & Sullivan, as of 2024, CHANDO is the third-largest Chinese cosmetics group by retail sales. Its flagship brand, CHANDO, has ranked among the top two Chinese beauty brands by retail sales every year from 2013 to 2024, showcasing the company’s resilience across industry cycles.

Over the past two decades, CHANDO Group has evolved into a comprehensive enterprise that encompasses independent raw material sourcing, R&D, and manufacturing, with a fully integrated digital operating system and efficient direct-to-consumer (DTC) channels. Leveraging its robust capabilities, the company has expanded its portfolio to include multiple brands, such as CHANDO, Perfection Research, Chunxia, Meisu, and Jichu, covering a wide range of product categories including skincare, cosmetics, personal care, men’s grooming, and baby care.

Technology-Driven Beauty Innovation: Consistent Breakthroughs in R&D

In a highly competitive China beauty market, CHANDO Group has remained a frontrunner by relentlessly driving brand innovation through technology. The company is committed to meeting consumers’ demand for products that deliver both efficacy and beauty. Amidst the rise of countless “internet celebrity” brands, CHANDO’s enduring market leadership is due to its unwavering focus on long-term strategy, putting consumers at the center, and continuously investing in core business elements that create differentiated consumer experiences.

Nowadays, CHANDO has a team of 154 highly skilled researchers with expertise in fields like life sciences, material sciences, and applied chemistry. The company has also formed strategic partnerships with renowned medical institutions, including Huashan Hospital and the National Children’s Medical Center (Fudan University Children’s Hospital).

Since 2013, CHANDO has been at the forefront of microbial fermentation research, with independent research centers in locations such as Shanghai and Nyingchi, Tibet. The company has successfully developed several proprietary core ingredients, including “Ximoin,” “Blue Copper Peptide,” and “Space Ginseng Yeast,” making it the first Chinese cosmetics company to hold independent intellectual property rights in yeast-based ingredients. In partnership with China’s aerospace program, CHANDO is also exploring skincare challenges in space environments, further pushing the boundaries of skincare science.

Digital Transformation: Leading Industry Innovation

In addition to its innovation in R&D, CHANDO Group’s sustained success is also attributed to its forward-thinking approach to industry transformation. Not satisfied with merely being a leader in offline beauty retail, the company launched its digital transformation strategy in 2019. With a “digital-driven decision-making” philosophy, CHANDO has worked to build a consumer-centric, agile, and continuously evolving organization. The company was among the first in the cosmetics industry to implement advanced digital management tools, such as “Unified Inventory” and “Cloud Stores”, setting new benchmarks for the industry.

CHANDO’s digital strategy has enabled the company to establish an end-to-end digital business operation, including supply chain management, inventory control, production management, sales and marketing, logistics, and consumer data analysis. This comprehensive digital framework has significantly improved operational efficiency and decision-making quality, enhancing the company’s overall performance.

Harvest Capital’s Deep Involvement: Boosting Quality and Efficiency

Harvest Capital strongly aligns with CHANDO Group’s development strategy, which focuses on “cultivating lifetime consumer value” and “driven by digitalization and technology.” The firm values the company’s solid R&D capabilities and admires the founder’s entrepreneurial spirit, which emphasizes focus, continuous innovation, and organizational evolution. Since 2021, Harvest Capital has conducted in-depth research on CHANDO Group, assembling a team of professionals from various fields—including business, finance, and legal experts—to provide strategic planning, comprehensive budget management, and organizational support.

Focused on improving operational efficiency, Harvest Capital has helped CHANDO establish a comprehensive budgeting system centered around ROE (return on equity). The team participates in monthly business review meetings, collaborating with internal teams to identify areas for improvement. Additionally, Harvest Capital has helped the company optimize its DTC channel investments and growth, incorporating advanced industry methodologies and best practices to improve data quality and enhance marketing efficiency. Notably, while continuing to expand its offline retail presence, CHANDO has successfully developed an effective DTC channel, with online sales now accounting for 68.8% of its revenue. The brand has performed particularly well in the rapidly growing content e-commerce sector.

In 2023, based on its deep understanding of the industry and CHANDO Group, Harvest Capital provided comprehensive recommendations for the company’s five-year strategic plan. These insights were well-received by CHANDO’s management and have helped shape a clear roadmap for the company’s high-quality development. Moving forward, Harvest Capital will continue to support CHANDO’s listing and further growth, leveraging its post-investment support systems and extensive resources in the consumer sector.

A Shared Vision for the Future: Building a World-Leading Beauty Group

According to CBNData, China beauty brands accounted for about 55.2% of the market share in 2024, securing a dominant position. However, the market concentration of the top five brands remains in the single digits, a stark contrast to the maturity of mature markets. This signals that the industry is entering a crucial stage, transitioning from a “mass rise” to “leader concentration.” In this transition, industry leaders with core technologies, full supply chain advantages, and digital capabilities will play a key role in market consolidation. Harvest Capital firmly believes that as beauty brands grow stronger, China will soon produce world-class beauty groups.

Despite macroeconomic pressures, the underlying demand for beauty and self-care remains strong and stable. For the mass market, rational consumption is becoming the norm, and consumers are increasingly seeking “high-quality, affordable” products. Brands that can deeply understand consumer needs, drive supply with demand, and consistently create value for consumers by offering high-quality products will emerge as the winners in any economic cycle. With over two decades of industry experience and a strong digital transformation advantage, CHANDO Group is well-positioned to lead this trend.

This collaboration is a strategic alignment based on a shared long-term vision: to build a leading beauty brand and establish a world-class enterprise. It also represents Harvest Capital’s commitment to supporting China’s consumption sector and empowering national brands.

As Harvest Capital’s founding partner and chairman, Alan Song Xiangqian, stated, “Consumption is the stabilizer and ballast of China’s economy. We remain confident in the long-term growth potential of beauty brands and are committed to supporting Chinese companies like CHANDO, which are driven by technology, digitalization, and long-term vision, to become world-class national brands.”

BOSTON, Oct. 13, 2025 /PRNewswire/ — Complete Genomics, a leading innovator in genomic sequencing, today announced at the American Society of Human Genetics Annual Meeting that it has added Houston-based Gene by Gene, a leading genetics laboratory, to its Sequencing Service Provider Program. 

The Complete Genomics Service Provider Program connects its customers to a network of service providers, offering access to high-quality sequencing services using Complete Genomics DNBSEQ™ sequencing platforms.

“We’re excited about partnering with Complete Genomics, which we believe will contribute to the growth of the sequencing market in the U.S.,” said Josh Wittner, president of Gene by Gene.

Having already processed more than 40,000 genomes using Complete Genomics’ DNBSEQ technology, Gene by Gene is performing a wide array of sequencing applications.  Over the last two years, Gene by Gene has been integral in providing feedback to the ongoing development of Complete Genomics’ technology, leading not only to chemistry improvements but also to product launches such as the recently announced T7+. As part of this next phase, Gene by Gene will be early adopters of multiple T7+ units to further enable their consistent new customer adoption and continued revenue growth.

“We continue to grow our Sequencing Service Provider Program, which enables customers to utilize DNBSEQ technology and receive accurate, cost-effective data quickly via our experienced partners,” said Rob Tarbox, vice president of product and marketing at Complete Genomics.

About Complete Genomics

Complete Genomics is a pioneering life sciences company that provides novel, complete sequencing solutions including sample and library preparation, lab automation, sequencing, and data analysis. The sequencing portfolio offers a full lineup of sequencers ranging from low, medium, and high throughput capacities, all powered by its proprietary DNBSEQ technology. More than 10,900 publications are based on DNBSEQ technology across a wide array of applications. To learn more, visit completegenomics.com.

* For Research Use Only. Not for use in diagnostic procedures.

About Gene by Gene

Gene by Gene is a world leader in genetic testing services with over 20 years of experience. Our laboratory holds accreditation from multiple agencies, including CAP, CLIA, New York State Department of Health, California Department of Public Health, and AABB. With a cutting-edge laboratory and highly trained team of experts, we are committed to excellence in the field of genetic analysis. To learn more about Gene by Gene, visit genebygene.com.

CHENGDU, China, Oct. 13, 2025 /PRNewswire/ — iRegene Therapeutics Co., Ltd. (“iRegene” or the “Company”) is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene’s lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both the NMPA and the FDA to treat Parkinson’s disease (PD). Recently, NouvNeu001 Phase I clinical data were presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS).

Excellent safety and tolerability were observed for up to 15 months post-transplantation, notably without the use of immunosuppressants after the sixth month. NouvNeu001 was administered via a stereotactically guided procedure, with bilateral injections into the posterior putamen through a single injection trajectory per hemisphere. PET imaging confirmed the long-term engraftment, survival and maturation of the transplanted cells. Significant clinical efficacy was observed, including marked improvements in MDS-UPDRS Part III motor scores. In the low-dose cohort, UPDRS-III scores improved by an average of 30.6 points in the OFF state (a 52.82% improvement from baseline) and 12.9 points in the ON state (a 54.67% improvement from baseline）at 12 months post-transplantation. Similarly, in the high-dose cohort, scores decreased by an average of 23.3 points (OFF) and 9.67 points (ON) at 9 months post-transplantation. These improvements were statistically significant, with continued improvement observed through 15 months post-treatment.

Dr. Meng Cai, Chief Medical Officer of iRegene Therapeutics, explained why the Phase I results of NouvNeu001 are so promising. He stated:

“The encouraging outcomes from the Phase I trial of NouvNeu001 can be attributed to iRegene’s unique chemical induction platform and optimized clinical strategies. iRegene uses a proprietary chemical inducer cocktail to generate high-purity A9 dopaminergic progenitor cells with enhanced functionality. In addition, the surgical procedure was specifically designed to utilize a single injection trajectory per hemisphere, significantly reducing potential surgical risks and related adverse events.”

Dr. Jun Wei, Chief Executive Officer of iRegene Therapeutics, added:

“The iRegene team is greatly encouraged by this important milestone. We remain fully committed to advancing the completion of the Phase II clinical trial and the international multi-center Phase I clinical trial，and achieving the next milestones in our mission to bring transformative therapies to patients with Parkinson’s disease.”

About NouvNeu001

iRegene’s flagship product, NouvNeu001, is the world’s first clinical-stage, iPSC-derived, allogeneic dopaminergic progenitor cell therapy for PD. NouvNeu001 received the China NMPA’s IND clearance to initiate Phase I/II in China on Aug 2023, and received the FDA IND clearance to initiate Phase I in USA on June 2024. In April 2025, iRegene launched a multicenter Phase II clinical trial in China (NCT06167681).

On August 15, 2025, NouvNeu001 was granted Fast Track Designation (FTD) from the U.S. FDA, becoming the first allogeneic iPSC-derived PD cell therapy worldwide to earn this recognition. This milestone follows the FDA’s Special Exemption (SE) granted in March 2024, further validating iRegene’s clinical data integrity, product quality system, and innovative therapeutic approach.

About iRegene Therapeutics

Founded in 2017 by a team of international professionals, iRegene Therapeutics is the earliest biotech in the world to apply ” Chemical induction” to precisely reprogram cell fate and optimize cellular functions. Leveraging this breakthrough platform, iRegene Therapeutics has built a robust pipeline targeting currently “incurable” diseases such as Parkinson’s disease and blindness. As a leader in chemical induction, iRegene’s proprietary system enables the efficient easy generation of human specific cell types with high purity, and enhanced cellular functionality, pioneering the next generation of chemically derived cell therapies.

BEIJING, Oct. 13, 2025 /PRNewswire/ — WiMi Hologram Cloud Inc. (NASDAQ: WiMi) (“WiMi” or the “Company”), a leading global Hologram Augmented Reality (“AR”) Technology provider, today announced that active exploration is underway in the field of Quantum Dilated Convolutional Neural Networks (QDCNN) technology. This technology is expected to break through the limitations of traditional convolutional neural networks in handling complex data and high-dimensional problems, bringing technological leaps to various fields such as image recognition, data analysis, and intelligent prediction.

The traditional Convolutional Neural Network (CNN) is a cornerstone in the field of deep learning. Through a combination of convolutional layers, pooling layers, and fully connected layers, it can automatically extract features from large amounts of data. In the convolutional layer, the convolution kernel slides over the input data, performing convolution operations to extract local features. The pooling layer reduces the data dimensions through downsampling, lowering computational load while preserving key information. The fully connected layer integrates the features processed by convolution and pooling, outputting the final classification or prediction results. However, with the explosive growth of data volume and the increasing complexity of problems, traditional CNNs are gradually facing bottlenecks in computational efficiency and feature extraction capabilities.

Quantum computing introduces the concept of quantum bits (qubits). Unlike the binary bits of traditional computers, qubits can exist in multiple superposition states, endowing quantum computers with powerful parallel computing capabilities. The Quantum Dilated Convolutional Neural Network (QDCNN) technology explored by WiMi ingeniously integrates the advantages of quantum computing into the traditional CNN architecture. In QDCNN, certain computational operations are performed by quantum processors. For example, in convolution operations, quantum gate operations are used to perform quantized computations on the convolution kernel and input data, enabling simultaneous processing of multiple data states, which significantly accelerates the feature extraction process. Quantum entanglement properties are also utilized to enhance information transfer and collaborative processing capabilities between different nodes in the network, allowing the network to more efficiently capture complex relationships within the data.

Through dilated convolution technology, the receptive field of the convolution kernel is expanded, enabling the acquisition of broader contextual information without increasing the number of parameters. This is highly effective for processing data with long-distance dependencies, such as natural language text and large-scale images. In Quantum Dilated Convolutional Neural Networks (QDCNN), quantum computing further enhances the effect of dilated convolution. Quantum algorithms can more precisely calculate the weight coefficients in dilated convolution, allowing the network to more accurately model complex features while expanding the receptive field. Traditional CNNs experience exponential growth in computational load when processing large-scale data. In contrast, QDCNN leverages the parallelism of quantum computing to complete convolution operations on massive datasets in a short amount of time.

Quantum Dilated Convolutional Neural Networks not only extract the features that traditional CNNs can obtain but also uncover hidden quantum-level feature information in the data. The superposition and entanglement states of quantum computing enable the network to analyze data from multiple perspectives simultaneously, identifying subtle feature differences that are difficult to detect with traditional methods. Due to quantum computing’s ability to explore a larger data feature space, the models built by QDCNN exhibit stronger generalization capabilities. When faced with new, unseen data, QDCNN models can better adapt and predict, reducing the occurrence of overfitting.

Achieving efficient collaboration between quantum computing and classical computing is a major challenge for QDCNN. In the future, WiMi will optimize the data transmission and task scheduling mechanisms between quantum computing and classical computing, rationally allocating computational tasks to allow quantum processors to focus on parts where quantum acceleration is significant, while classical processors handle traditional computational tasks, thereby improving the overall operational efficiency of the system. Additionally, WiMi will reduce algorithm complexity by optimizing algorithm structures, adopting layered designs, and implementing modular programming. At the same time, research into distributed quantum computing technology will enable quantum computing tasks to be distributed across multiple quantum processors for parallel processing, enhancing the scalability of QDCNN and making it capable of meeting the demands of large-scale data processing and complex application scenarios.

With continuous exploration and innovation in Quantum Dilated Convolutional Neural Network technology, it is expected to find wide applications in more fields. For example, in the medical field, Quantum Dilated Convolutional Neural Network technology can be used for molecular structure analysis and disease prediction in drug development, accelerating the process of new drug discovery and improving healthcare standards. In the field of intelligent transportation, it can enable more accurate traffic flow prediction and intelligent driving decisions, enhancing traffic safety and efficiency. In environmental protection, it can analyze large amounts of environmental data to predict climate change trends, providing strong support for formulating environmental policies.

About WiMi Hologram Cloud

WiMi Hologram Cloud Inc. (NASDAQ: WiMi) focuses on holographic cloud services, primarily concentrating on professional fields such as in-vehicle AR holographic HUD, 3D holographic pulse LiDAR, head-mounted light field holographic devices, holographic semiconductors, holographic cloud software, holographic car navigation, metaverse holographic AR/VR devices, and metaverse holographic cloud software. It covers multiple aspects of holographic AR technologies, including in-vehicle holographic AR technology, 3D holographic pulse LiDAR technology, holographic vision semiconductor technology, holographic software development, holographic AR virtual advertising technology, holographic AR virtual entertainment technology, holographic ARSDK payment, interactive holographic virtual communication, metaverse holographic AR technology, and metaverse virtual cloud services. WiMi is a comprehensive holographic cloud technology solution provider. For more information, please visit http://ir.wimiar.com.

Translation Disclaimer

The original version of this announcement is the officially authorized and only legally binding version. If there are any inconsistencies or differences in meaning between the Chinese translation and the original version, the original version shall prevail. WiMi Hologram Cloud Inc. and related institutions and individuals make no guarantees regarding the translated version and assume no responsibility for any direct or indirect losses caused by translation inaccuracies.